Publicaciones (231) Publicaciones de PATRICIA ESMERALDA CARREIRA DELGADO

2024

  1. Diffusing Capacity of the Lungs for Carbon Monoxide and Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in the EUSTAR Cohort of Patients With Systemic Sclerosis

    Chest, Vol. 166, Núm. 4, pp. 837-844

  2. Does the Impact of COVID-19 on Patients With Systemic Sclerosis Change Over Time?

    Arthritis Care and Research, Vol. 76, Núm. 1, pp. 88-97

  3. Experiences of telehealth during and after the COVID-19 pandemic and preferences for future care of people with systemic sclerosis: a cross-sectional study

    The Lancet Rheumatology

  4. Minimal Detectable Changes of the Health Assessment Questionnaire–Disability Index, Patient-Reported Outcomes Measurement Information System-29 Profile Version 2.0 Domains, and Patient Health Questionnaire-8 in People With Systemic Sclerosis: A Scleroderma Patient-Centered Intervention Network Cohort Cross-Sectional Study

    Arthritis Care and Research

  5. Moderators of Loneliness Trajectories in People with Systemic Sclerosis During the COVID-19 Pandemic: A SPIN COVID-19 Cohort Longitudinal Study

    International Journal of Behavioral Medicine

  6. Similarities and differences between systemic juvenile idiopathic arthritis and adult-onset Still’s disease: a multicenter Spanish study

    Rheumatology International

  7. Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients

    Seminars in Arthritis and Rheumatism, Vol. 68

  8. The association of outdoor temperature and self-reported Raynaud's phenomenon severity among people with systemic sclerosis: a Scleroderma Patient-centered Intervention Network Cohort study

    The Lancet Rheumatology, Vol. 6, Núm. 10, pp. e684-e692

2023

  1. Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies

    Rheumatology (United Kingdom), Vol. 62, Núm. 1, pp. 243-255

  2. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research

    Chest, Vol. 163, Núm. 3, pp. 586-598

  3. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database

    JAMA dermatology, Vol. 159, Núm. 8, pp. 837-847

  4. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

    Clinical and experimental rheumatology, Vol. 41, Núm. 3, pp. 543-553

  5. Gender biases in Spanish rheumatology: Perception and facts

    Reumatologia Clinica, Vol. 19, Núm. 7, pp. 392-401

  6. Glucocorticoids prescribing practices in systemic sclerosis: an analysis of the EUSTAR database

    Rheumatology (Oxford, England), Vol. 62, Núm. 4, pp. 1559-1567

  7. Immunoglobulins in systemic sclerosis management. A large multicenter experience

    Autoimmunity Reviews, Vol. 22, Núm. 11

  8. Patterns of patient-reported symptoms and association with sociodemographic and systemic sclerosis disease characteristics: a scleroderma Patient-centered Intervention Network (SPIN) Cohort cross-sectional study

    eClinicalMedicine, Vol. 62

  9. Sex influence on outcomes of patients with systemic sclerosis-associated interstitial lung disease: A EUSTAR database analysis

    Rheumatology (United Kingdom), Vol. 62, Núm. 7, pp. 2483-2491

  10. The Impact of Progressive Pulmonary Fibrosis in Systemic Sclerosis–Associated Interstitial Lung Disease

    Journal of Clinical Medicine, Vol. 12, Núm. 20